Misplaced Pages

Mozavaptan: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 22:08, 14 October 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref') per Chem/Drugbox validation (report errors or bugs)← Previous edit Latest revision as of 00:15, 5 November 2022 edit undoEntranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers173,243 edits +sd 
(19 intermediate revisions by 16 users not shown)
Line 1: Line 1:
{{short description|Chemical compound}}
{{Drugbox {{Drugbox
| Verifiedfields = changed
| verifiedrevid = 455185272 | verifiedrevid = 462255885
| IUPAC_name = ''N''--2-methylbenzamide | IUPAC_name = ''N''--2-methylbenzamide
| image = Mozavaptan structure.svg | image = Mozavaptan structure.svg
Line 24: Line 26:


<!--Identifiers--> <!--Identifiers-->
| IUPHAR_ligand = 2197
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 137975-06-5 | CAS_number = 137975-06-5
| ATC_prefix = none | ATC_prefix = none
Line 32: Line 36:
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = WRNXUQJJCIZICJ-UHFFFAOYSA-N | StdInChIKey = WRNXUQJJCIZICJ-UHFFFAOYSA-N
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 420762
| PubChem = 119369 | PubChem = 119369
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
Line 43: Line 49:
| chemical_formula = | chemical_formula =
| C=27 | H=29 | N=3 | O=2 | C=27 | H=29 | N=3 | O=2
| smiles = Cc1ccccc1C(=O)Nc2ccc(cc2)C(=O)N3c4ccccc4C(CCC3)N(C)C
| molecular_weight = 427.53 g/mol
| smiles = CC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)N3CCCC(C4=CC=CC=C43)N(C)C
| InChI = 1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31)
}} }}


'''Mozavaptan''' (]) is a ] marketed by ]. In Japan, it was approved in October ] for ] (low blood ] levels) caused by ] (SIADH) due to ADH producing tumors. '''Mozavaptan''' (]) is a ] marketed by ]. In Japan, it was approved in October 2006 for ] (low blood ] levels) caused by ] (SIADH) due to ADH producing tumors.


==References== ==References==
* {{cite journal | vauthors = Spreitzer H | date = November 20, 2006 | title = Neue Wirkstoffe - Conivaptan | journal = Österreichische Apothekerzeitung | issue = 24/2006 | language = German }}
* {{cite journal
* {{cite web | title = Conivaptan hydrochloride | url = http://www.prous.com/molecules/default.asp?ID=153 | publisher = Prous Science | work = Molecule of the Month | date = November 2006 |archive-url = https://web.archive.org/web/20120213003638/http://www.prous.com/molecules/default.asp?ID=153|archive-date = 2012-02-13}}
| author = H. Spreitzer

| date = November 20, 2006
| title = Neue Wirkstoffe - Conivaptan
| journal = Österreichische Apothekerzeitung
| issue = 24/2006
| language = German
}}
*


{{Diuretics}} {{Diuretics}}
{{Oxytocin and vasopressin receptor modulators}}
{{Neuropeptide agonists and antagonists}}


] ]
⚫ ]
] ]
]
] ]
]
⚫ ]




{{antihypertensive-stub}} {{antihypertensive-stub}}

]

Latest revision as of 00:15, 5 November 2022

Chemical compound Pharmaceutical compound
Mozavaptan
Clinical data
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
IUPAC name
  • N--2-methylbenzamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC27H29N3O2
Molar mass427.548 g·mol
3D model (JSmol)
SMILES
  • Cc1ccccc1C(=O)Nc2ccc(cc2)C(=O)N3c4ccccc4C(CCC3)N(C)C
InChI
  • InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31)
  • Key:WRNXUQJJCIZICJ-UHFFFAOYSA-N
  (what is this?)  (verify)

Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.

References

  • Spreitzer H (November 20, 2006). "Neue Wirkstoffe - Conivaptan". Österreichische Apothekerzeitung (in German) (24/2006).
  • "Conivaptan hydrochloride". Molecule of the Month. Prous Science. November 2006. Archived from the original on 2012-02-13.


Diuretics (C03)
Sulfonamides
(and etacrynic acid)
CA inhibitors (at PT)
Loop (Na-K-Cl at AL)
Thiazides (Na-Cl at DCT,
Calcium-sparing)
Thiazide-likes (primarily DCT)
Potassium-sparing (at CD)
ESC blockers
Aldosterone antagonists
Osmotic diuretics (PT, DL)
Vasopressin receptor inhibitors
(DCT and CD)
Other
Combination products
Oxytocin and vasopressin receptor modulators
Oxytocin
Vasopressin
V1A
V1B
V2
Unsorted
Others


Stub icon

This antihypertensive-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: